CY1123636T1 - Διαθεσιμες πολυαμινες - Google Patents

Διαθεσιμες πολυαμινες

Info

Publication number
CY1123636T1
CY1123636T1 CY20201101192T CY201101192T CY1123636T1 CY 1123636 T1 CY1123636 T1 CY 1123636T1 CY 20201101192 T CY20201101192 T CY 20201101192T CY 201101192 T CY201101192 T CY 201101192T CY 1123636 T1 CY1123636 T1 CY 1123636T1
Authority
CY
Cyprus
Prior art keywords
salts
agent
pharmaceutical
polyamines available
hydrophobic
Prior art date
Application number
CY20201101192T
Other languages
English (en)
Inventor
Mark R. Burns
Original Assignee
Aminex Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aminex Therapeutics, Inc. filed Critical Aminex Therapeutics, Inc.
Publication of CY1123636T1 publication Critical patent/CY1123636T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αποκαλύπτονται εις το παρόν φαρμακευτικά άλατα ενός κατιονικού πρωτονιωμένου φαρμακευτικού παράγοντα πολυαμίνης και ενός ανιονικού οργανικού καρβοξυλικού το οποίο είναι υδρόφοβο όταν είναι σε πρωτονιωμένη μορφή, ειδικότερα δε κατάλληλα προσαρμοσμένα για εκ του στόματος χορήγηση, όπου αυτά τα άλατα έχουν ικανοποιητική βιοδιαθεσιμότητα σε στερεές μορφές δοσολογίας και μπορεί να χρησιμοποιηθούν στην αγωγή του καρκίνου και άλλων ιατρικών καταστάσεων για τις οποίες ο φαρμακευτικός παράγων προορίζεται.
CY20201101192T 2016-03-25 2020-12-16 Διαθεσιμες πολυαμινες CY1123636T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313657P 2016-03-25 2016-03-25
PCT/US2017/023250 WO2017165313A1 (en) 2016-03-25 2017-03-20 Bioavailable polyamines

Publications (1)

Publication Number Publication Date
CY1123636T1 true CY1123636T1 (el) 2022-03-24

Family

ID=59899774

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101192T CY1123636T1 (el) 2016-03-25 2020-12-16 Διαθεσιμες πολυαμινες

Country Status (20)

Country Link
US (3) US10632145B2 (el)
EP (2) EP3785706B1 (el)
JP (1) JP6949098B2 (el)
KR (1) KR102454783B1 (el)
CN (1) CN109069594B (el)
AU (1) AU2017236905B2 (el)
CA (1) CA3015849A1 (el)
CY (1) CY1123636T1 (el)
DK (2) DK3785706T3 (el)
EA (1) EA037149B1 (el)
ES (2) ES2836289T3 (el)
HR (1) HRP20201844T1 (el)
HU (1) HUE052620T2 (el)
IL (1) IL261512A (el)
LT (1) LT3432914T (el)
MX (1) MX2018010768A (el)
PL (1) PL3432914T3 (el)
PT (1) PT3432914T (el)
SI (1) SI3432914T1 (el)
WO (1) WO2017165313A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165313A1 (en) 2016-03-25 2017-09-28 Aminex Therapeutics Inc. Bioavailable polyamines
AU2021354039A1 (en) 2020-09-30 2023-05-25 Aminex Therapeutics, Inc. Combination drug substance of polyamine transport inhibitor and dfmo
US20230321012A1 (en) * 2021-12-01 2023-10-12 Aminex Therapeutics, Inc. Methods To Treat Cancer With AMXT 1501 and DFMO

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3517M (fr) * 1962-12-07 1965-09-06 Hoffmann La Roche Médicament a base de compositions vitaminées.
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4590288A (en) 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
HU200093B (en) 1983-12-20 1990-04-28 Adam Kovacs Process for production of medical compositions against tumour
EP0187332B1 (en) 1985-01-10 1989-02-01 Molecular Diagnostics, Inc. Photochemical method of labelling nucleic acids for detection in hybridization assays
US4818770A (en) 1986-10-22 1989-04-04 Boyce Thompson Institute For Plant Research Prevention of a plant disease by specific inhibition of fungal polyamine biosynthesis
US5342945A (en) 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
JP3072108B2 (ja) 1988-12-09 2000-07-31 ダイセル化学工業株式会社 新規なポリアミン化合物及びグルタミン酸レセプター遮断剤
AU5957390A (en) 1989-07-03 1991-02-06 New York University Use of polyamines as ionic-channel regulating agents
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US5648394A (en) 1993-05-27 1997-07-15 Boxall; Brian Alfred Topical composition for inhibiting hair growth
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
CA2182680A1 (en) 1994-02-08 1995-08-17 Alan L. Mueller Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1996022926A1 (en) 1995-01-25 1996-08-01 Sealed Air Corporation Inflatable cushion and method of making same
US5583239A (en) 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
JPH09235271A (ja) 1996-02-29 1997-09-09 Suntory Ltd ポリアミン誘導体
DE69721780T2 (de) 1996-03-14 2004-03-25 Schering-Plough Healthcare Products, Inc., Memphis Präparat und verfahren zur künstlichen hautbräunung
JP4044728B2 (ja) 1997-07-15 2008-02-06 メディクエスト セラピューティックス インク 治療および診断薬剤としての新規なポリアミンアナログ
US7208528B1 (en) 1997-07-15 2007-04-24 Mediquest Therapeutics, Inc. Polyamine analogues as therapeutic and diagnostic agents
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
AU7131698A (en) 1998-04-21 1999-11-08 Ilex Oncology, Inc. Polyamine transport inhibitors
AU1998899A (en) 1998-12-10 2000-06-26 Ilex Oncology, Inc. Polyamine transport inhibitors
EP1159261B1 (en) 1999-02-05 2005-11-02 Oridigm Corporation Antizyme modulators and their use
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US6872852B2 (en) 2000-03-24 2005-03-29 Mediquest Therapeutics, Inc. Polyamine analogues as cytotoxic agents
USRE43327E1 (en) 2001-01-08 2012-04-24 Aminex Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US7432302B2 (en) 2001-01-08 2008-10-07 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
CN100582084C (zh) * 2001-01-08 2010-01-20 麦迪凯斯特治疗学股份有限公司 疏水性多胺类似物及其使用方法
US7144920B2 (en) 2002-09-23 2006-12-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US6914079B2 (en) 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US6919483B2 (en) 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
AU2005333545A1 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US7411002B2 (en) 2006-06-07 2008-08-12 The University Of Kansas Polycationic sulfonamides and use thereof
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
DE102009000505A1 (de) * 2009-01-30 2010-08-05 Evonik Goldschmidt Gmbh Zusammensetzungen enthaltend Reaktionsprodukte aus Alkylamidoaminen, Alkylaminoimidazolinen und freiem Amin sowie deren Verwendung
NZ597488A (en) 2009-07-16 2014-10-31 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US20110256161A1 (en) * 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
US9439433B2 (en) * 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
WO2017165313A1 (en) 2016-03-25 2017-09-28 Aminex Therapeutics Inc. Bioavailable polyamines

Also Published As

Publication number Publication date
EA201892175A1 (ru) 2019-02-28
LT3432914T (lt) 2020-12-10
AU2017236905B2 (en) 2024-03-28
DK3785706T3 (da) 2023-09-11
PT3432914T (pt) 2020-12-24
EA037149B1 (ru) 2021-02-11
US10632145B2 (en) 2020-04-28
PL3432914T3 (pl) 2021-03-08
ES2955255T3 (es) 2023-11-29
CN109069594A (zh) 2018-12-21
SI3432914T1 (sl) 2021-01-29
JP6949098B2 (ja) 2021-10-13
EP3432914B1 (en) 2020-09-23
HUE052620T2 (hu) 2021-05-28
US20200352983A1 (en) 2020-11-12
JP2019513153A (ja) 2019-05-23
EP3432914A1 (en) 2019-01-30
EP3432914A4 (en) 2019-11-13
EP3785706A1 (en) 2021-03-03
DK3432914T3 (da) 2020-11-30
US11395834B2 (en) 2022-07-26
CN109069594B (zh) 2022-03-08
EP3785706B1 (en) 2023-06-07
WO2017165313A1 (en) 2017-09-28
AU2017236905A1 (en) 2018-09-06
ES2836289T3 (es) 2021-06-24
IL261512A (en) 2018-10-31
HRP20201844T1 (hr) 2021-04-02
KR102454783B1 (ko) 2022-10-13
CA3015849A1 (en) 2017-09-28
MX2018010768A (es) 2018-11-29
KR20180123133A (ko) 2018-11-14
US20230088829A1 (en) 2023-03-23
US20190008892A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
CY1123636T1 (el) Διαθεσιμες πολυαμινες
CY1125292T1 (el) Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1124675T1 (el) Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
AU2022202403A1 (en) Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medicinal Disorders
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
BR112019005247A2 (pt) terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco
CY1120490T1 (el) Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
CY1124580T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1121921T1 (el) Φαρμακευτικα σκευασματα
ES2582287R2 (es) Procedimiento de obtención y composición farmacéutica de nanopartículas poliméricas para el tratamiento de dolor neuropático producido por compresión nerviosa periférica
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
CY1121371T1 (el) Σταθερο σκευασμα για παρεντερικη χορηγηση ταπενταδολης
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine